Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients
- PMID: 33482867
- PMCID: PMC7820818
- DOI: 10.1186/s13054-021-03470-3
Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients
Conflict of interest statement
The authors declare that they have no competing interests. H.A.O. declares having received fees for medical trainings from the laboratories AMOMED.
Figures
References
-
- Sasao J, Tarver SD, Kindscher JD, Taneyama C, Benson KT, Goto H. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anaesth. 2001;48(10):985–989. doi: 10.1007/BF03016588. - DOI - PubMed
-
- Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, et al. Efficacy and safety of landiolol, an ultra-short-acting beta1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2020;9:863–872. doi: 10.1016/S2213-2600(20)30037-0. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
